| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
We are dedicated to health and to working in consultation with health professionals. We are committed to responsibility, through our secure non-transferable medical cannabis access card system. A system we are establishing in consultation with law enforcement to achieve national recognition.
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.
Cerber-Net is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fastgen Corporation is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.